CGEN - Compugen

-

$undefined

N/A

(N/A)

Compugen NasdaqCM:CGEN Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Location: Azrieli Center, Holon, 5885849, Israel | Website: https://cgen.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

40.26M

Cash

103.7M

Avg Qtr Burn

N/A

Short % of Float

1.70%

Insider Ownership

2.12%

Institutional Own.

18.14%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Rilvegostomig (PD-1/TIGIT) Details
Cancer, Biliary Tract Cancer

Phase 3

Data readout

Rilvegostomig (PD-1/TIGIT) Details
Cancer, Biliary Tract Cancer

Phase 2b

Data readout

Rilvegostomig (PD-1/TIGIT) Details
Non-small cell lung carcinoma, Cancer, Hepatobiliary cancer

Phase 2

Data readout

COM701 + Opdivo (nivolumab) +/- BMS-986207 Details
Endometrial cancer, Cancer, Ovarian cancer

Phase 1/2

Update

COM701 + Opdivo (nivolumab) Details
Cancer, Solid tumor/s, Metastatic breast cancer

Phase 1b

Update

COM902 (TIGIT) Details
Cancer, Advanced malignancies

Phase 1

Data readout

COM701+COM902 +Pembrolizumab Details
Cancer, Platinum-resistant ovarian cancer

Phase 1

Data readout

COM701+COM902 +Pembrolizumab Details
Cancer, Colorectal cancer

Phase 1

Update

COM503 Details
Cancer, Solid tumor/s

Phase 1

Initiation

COM701 (PVRIG) Details
Ovarian cancer, Colorectal cancer , Non-small cell lung carcinoma, Breast cancer, Endometrial cancer, Cancer

Failed

Discontinued